Supplementary Materials

Supplementary Material for:

A replication-defective human cytomegalovirus vaccine for prevention of congenital infection

Dai Wang*, Daniel C. Freed, Xi He, Fengsheng Li, Aimin Tang, Kara S. Cox, Sheri A. Dubey, Suzanne Cole, Muneeswara Babu Medi, Yaping Liu, Jingyuan Xu, Zhi-Qiang Zhang, Adam C. Finnefrock, Liping Song, Amy S. Espeseth, John W. Shiver, Danilo R. Casimiro, Tong-Ming Fu*

*Corresponding author. Email: dai_wang{at}merck.com (D.W.); tong-ming_fu{at}merck.com (T.-M.F.)

Published 26 October 2016, Sci. Transl. Med. 8, 362ra145 (2016)
DOI: 10.1126/scitranslmed.aaf9387

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Schematic diagram on the construction of epithelial-tropic AD169 virus.
  • Fig. S2. Effect of Shld-1 concentration on progeny production of ddFKBP fusion mutants.
  • Fig. S3. Genetic map of V160, MAD169, and wild-type HCMV.
  • Fig. S4. Comparison of epithelial and fibroblast neutralization titers by V160 or gB vaccines in rhesus macaques.
  • Fig. S5. Kinetics of anti-beMAD or anti-gB antibodies after V160 vaccination.
  • Fig. S6. V160 infectivity and progeny production in the absence of Shld-1.
  • Fig. S7. High-throughput screening of medicinal compound collection.
  • Fig. S8. Potency of Shld-1 and tacrolimus (FK506) in rescuing V160.
  • Table S1. Construction and characterization of ddFKBP fusion mutants.
  • Table S2. Effect of MOI on Shld-1 dependent V160 replication.
  • Table S3. Minimum Shld-1 and tacrolimus (FK506) concentration required to rescue V160.
  • Table S4. ELISPOT responder rates to FKBP versus gB antigens.

[Download PDF]